ResultsIQ

ResultsIQ › Latest results › Sudeep Pharma Limited

Sudeep Pharma Limited Q3 FY26 results deck summary

NSE: SUDEEPPHRM · BSE: 544619

Results deck of 7 Feb 2026, summarised by AI from the filing.

Q3 FY26 Total Income ₹179.2 cr, up 52% YoY, with EBITDA ₹66.8 cr and PAT ₹47.7 cr.

Key takeaways

  1. Guidance Greenfield facility at Nandesari expected to be commissioned by Q4 FY26.
  2. Change Groundbreaking for Battery Materials Plant at Dahej on January 23, 2026.
  3. Driver Healthy demand across both business segments drove revenue growth.
  4. Risk China dominates global LFP precursor and cathode material production.

Original filing on BSE

Sudeep Pharma Limited Q1 FY27 results

As filed: Revenue ₹158 cr, EBITDA ₹54.9 cr, PAT ₹40.6 cr, EBITDA margin 34.7%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹158 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹182 cr, EBITDA ₹62.6 cr, PAT ₹48.5 cr, EBITDA margin 34.3%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹182 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +26.2% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹172 cr, EBITDA ₹60.0 cr, PAT ₹47.7 cr, EBITDA margin 34.8%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹172 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −8.7% in 28 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹163 cr, EBITDA ₹56.0 cr, PAT ₹47.0 cr, EBITDA margin 34.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹163 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −14.7% in 28 days (Nifty 500: −0.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Sudeep Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.